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BACKGROUND: The association between gall bladder removal (cholecystectomy) and hepatocellular carcinoma warrants investigation.
An increased intrahepatic bile duct pressure following cholecystectomy might cause chronic inflammation in the surrounding liver
tissue, which might induce cancer development.
METHODS: A nationwide Swedish population-based cohort study in 1965–2008 included 345251 patients undergoing cholecys-
tectomy because of gallstone. The number of observed hepatocellular carcinoma cases was divided by the expected number,
calculated from the corresponding background Swedish population, thus providing standardised incidence ratios (SIRs) with 95%
confidence intervals (CIs).
RESULTS: During follow-up of 4854969 person-years, 333 new cases of hepatocellular carcinoma were identified, rendering an overall
increased risk (SIR 1.24, 95% CI: 1.11–1.38). The risk increased with longer follow-up (P for trend¼0.003). Among patients who
underwent cholecystectomy 30–43 years earlier, SIR was 2.00 (95% CI: 1.32–2.87). The results were similar after exclusion of
15634 patients with any recorded risk factor, that is, diabetes, obesity, hepatitis, liver cirrhosis, alcoholism, or blood transfusion.
CONCLUSION: Cholecystectomy might be associated with a long-term increased risk of hepatocellular carcinoma.
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This study addresses the hypothesis that surgical removal of the
gall bladder (cholecystectomy) for gallstone disease is associated
with an increased risk of developing hepatocellular carcinoma.
Cholecystectomy is one of the most common surgical procedures
performed in the West. Hepatocellular carcinoma has the fifth
highest incidence of any cancer globally and is the third most
common reason for cancer death globally (El-Serag and Rudolph,
2007). Its incidence is increasing in the United States (McGlynn
et al, 2001). However, in Sweden, the incidence is lower (about 3
per 100000 persons and year). The only established risk factors for
hepatocellular carcinoma are diabetes, obesity, hepatitis, liver
cirrhosis, aflatoxin, and alcoholism (El-Serag and Rudolph, 2007).
The relation between cholecystectomy and hepatocellular carcino-
ma merits investigation, since an association is biologically
plausible. Cholecystectomy is typically followed by increased
pressure in and dilation of the intrahepatic bile ducts (Tanaka
et al, 1984), which in turn might cause chronic inflammation in the
surrounding liver tissue. Such inflammation could induce
proliferation of the liver cells (hepatocytes) and cause hepatocel-
lular carcinoma (El-Serag and Rudolph, 2007). A cohort study
from the Danish National Registry found a possible increase in risk
of unspecified primary liver cancer in patients who had undergone
cholecystectomy, while no increase was found in a cohort study
from the United Kingdom (Chow et al, 1999; Goldacre et al, 2005).
However, these studies were unable to evaluate long-term effects
and made no distinction between the histological types hepato-
cellular carcinoma and intrahepatic cholangiocarcinoma. Thus, no
previous study has addressed the specific relation between
cholecystectomy and hepatocellular carcinoma. We conducted a
large, population-based cohort study with long-term follow-up to
clarify this potential association.
PATIENTS AND METHODS
As described in detail elsewhere (Freedman et al, 2001), patients
undergoing cholecystectomy because of gallstone disease were
identified through the Swedish Patient Registry, which contains
data on 99% of all hospitalisations and surgical procedures
performed in Sweden since 1965 (Swedish Board of Health and
Welfare, 2009). Each cohort member was followed up until the first
occurrence of any cancer diagnosis, death, emigration, or until the
end of the study period (31 December 2008). Information on
cancer diagnosis was obtained from the Swedish Cancer Registry,
which was initiated in 1958 and has an at least 98% completeness
rate (Barlow et al, 2009). The tumour evaluated was primary liver
cancer of the hepatocellular type (code 155.0 and histological code
066 according to the International Classification of Diseases,
version 7). Information on dates of death and emigration was
obtained by referral to the Swedish Total Population Registry,
which is 100% complete and is constantly updated. All person-time
and cancers identified during the first year of follow-up were
excluded to allow a minimum latency interval between exposure
and outcome and to avoid bias due to earlier detection of non-
symptomatic tumours. The personal identity number, a unique
identifier for each resident in Sweden, allowed each cohort
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2009). Standardised incidence ratio (SIR), that is, the ratio of the
observed to the expected number of cases, was used to estimate
relative risk. The expected number of cases was calculated by
multiplying the observed person-years by age in 5 year groups,
gender, and calendar years-specific cancer incidence rates. These
rates were derived from the entire Swedish population through the
Swedish Cancer Registry. Confidence intervals (CIs) of the SIRs
were calculated on the assumption that the observed number of
cancer cases followed a Poisson distribution (Breslow and Day,
1987). A test for trend with increased calendar time was performed
(Breslow and Day, 1987). The regional ethics committee in
Stockholm approved the study.
RESULTS
The cholecystectomy cohort included 345251 people who were
followed up for an average of 15.1 years (range 1–43 years).
Together, they contributed 4854969 person-years at risk. The mean
age at cholecystectomy was 52 years (50 in women and 57 in men),
and 67% of patients were women. During the entire follow-up
period, 333 new cases of hepatocellular carcinoma were identified
after the first year. There was a statistically significant increased
overall risk of hepatocellular carcinoma compared with the
corresponding background population (SIR 1.24, 95% CI: 1.11–1.38;
Table 1). During the first decade after cholecystectomy, no
significantly increased risk was found, but thereafter the risk
gradually increased with longer follow-up time (P for tren-
d¼0.003). Among patients who had undergone cholecystectomy
at least 30 years earlier, the SIR of hepatocellular carcinoma was
increased two-fold compared with the corresponding background
population (SIR 2.00, 95% CI: 1.32–2.87). The association was
found only in younger age groups, and was stronger in females
(Table 1).
Analyses were repeated after excluding 15634 patients from the
cohort who had any recorded diagnosis of diabetes, obesity,
hepatitis, liver cirrhosis, or alcoholism before the cholecystectomy,
or blood transfusion, as these conditions could confound the
association between cholecystectomy and hepatocellular carcino-
ma. Similar results were observed; the increase in SIRs with
increasing exposure time after cholecystectomy was as evident as
in the total cohort (Table 2). Among patients with the longest
exposure time (i.e., those who had a cholecystectomy at least 30
years earlier) the SIR was 1.93 (95% CI: 1.27–2.81; Table 2).
DISCUSSION
This study provides evidence suggesting there is an increased
long-term risk of developing hepatocellular carcinoma among
patients who have undergone cholecystectomy.
The population-based cohort design, the high validity and
completeness of the databases used, the large size of the cohort,
and the long and complete follow-up of all participants are among
the methodological advantages of the study. Confounding is a
particular threat to observational research. Potential confounding
by age, sex, and calendar year was adjusted for in the study design.
Conditions related with hepatocellular carcinoma, that is, hepatitis
B and C infection, alcohol consumption, liver cirrhosis, obesity,
diabetes mellitus, and blood transfusion (El-Serag and Rudolph,
2007), should not act as confounders in the study since we
evaluated confounding by these risk factors by excluding patients
with a recorded diagnosis of at least one of these conditions, and
found no support for confounding being responsible for the
association. However, this exclusion may not be complete, since all
patients with these conditions might not be hospitalised and
hospitalisation might change over time. Thus, some level of
residual confounding from these factors cannot be excluded. Bias
due to earlier detection of hepatocellular carcinoma as part of the
cholecystectomy was unlikely as there was a lack of association
initially after surgery. Moreover, we excluded the first year after
cholecystectomy to prevent detection bias. The risk of tumour
misclassification was negligible, since only primary liver cancers
with a histologically verified hepatocellular carcinoma were
considered in the study. Finally, chance is an unlikely explanation for
t h ea s s o c i a t i o n ,b e c a u s eo ft h el a r g es a m p l es i z ea n dt h ed o s e–r e s p o n s e
Table 1 Risk of hepatocellular carcinoma among 345251 people
patients who had a gall bladder removal (cholecystectomy) during the
period 1965–2008 in Sweden, expressed as standardised incidence ratio
(SIR) with 95% confidence interval (CI)
Hepatocellular carcinoma
Characteristic Person-years Number SIR (95% CI)
All 4854969 333 1.24 (1.11–1.38)
Gender
Male 1418031 186 1.18 (1.01–1.36)
Female 3436938 147 1.34 (1.13–1.57)
Age at entry (years)
o60 3654343 176 1.46 (1.25–1.69)
60–69 785219 100 1.20 (0.98–1.46)
X70 415407 57 0.89 (0.68–1.16)
Years after cholecystectomy
1–4 1194909 60 1.10 (0.84–1.41)
5–9 1145868 63 1.02 (0.78–1.30)
10–19 1498022 113 1.24 (1.02–1.48)
20–29 762266 69 1.49 (1.16–1.89)
X30 253904 28 2.00 (1.32–2.87)
All person-time and cancers accrued during the first year of follow-up were excluded.
Table 2 Risk of hepatocellular carcinoma among 329617 people
patients who had a gall bladder removal (cholecystectomy) during the
period 1965–2008 in Sweden after exclusion of 15634 persons with any
recorded diagnosis of diabetes, obesity, hepatitis, liver cirrhosis, or
alcoholism before the cholecystectomy, or possible blood transfusion
during or after the cholecystectomy
Hepatocellular carcinoma
Characteristic Person-years Number SIR (95% CI)
All 4732507 298 1.14 (1.02–1.28)
Gender
Male 1368768 165 1.08 (0.92–1.26)
Female 3363739 133 1.23 (1.03–1.46)
Age at entry (years)
o60 3570621 163 1.38 (1.17–1.60)
60–69 763071 89 1.10 (0.88–1.35)
X70 398814 46 0.75 (0.55–1.00)
Years after cholecystectomy
1–4 1149673 46 0.89 (0.65–1.18)
5–9 1111908 50 0.84 (0.62–1.10)
10–19 1466894 108 1.21 (0.99–1.45)
20–29 752036 67 1.47 (1.14–1.87)
X30 251996 27 1.93 (1.27–2.81)
All person-time and cancers accrued during the first year of follow-up were excluded.
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not be dismissed for methodological reasons.
The lack of association seen during the first 10 years following
exposure (cholecystectomy) and the gradually increasing incidence
of invasive hepatocellular carcinomas after 10 years argue in
favour of a true association. To the best of our knowledge, no
previous study has addressed a possible relation between
cholecystectomy and hepatocellular carcinoma. Therefore, the
finding needs to be confirmed by future research before
conclusions can be drawn and it is too early to consider any
potential clinical recommendations. Two previous cohort studies
investigated cholecystectomy in relation to primary liver cancer
without specifying the histological type (Chow et al, 1999; Goldacre
et al, 2005). A Danish study found a statistically non-significant
increased risk, while a UK study found no increased risk after
excluding the first 2 years of follow-up. However, since the number
of hepatocellular carcinoma cases was limited in these two studies
(48 and 38, respectively) and the follow-up time was short, it was
not possible to evaluate any long-term effects.
If the association is true, a potential pathway might involve
chronic inflammation. Chronic inflammation is an accepted
carcinogenic mechanism for several types of cancer, including
hepatocellular carcinoma, and cell proliferation is present in most
liver disease as a consequence of chronic inflammation. Cholecys-
tectomy is typically followed by dilation of the common biliary
duct and a rise in bile duct pressure, both of which might increase
the risk of chronic inflammation and cell proliferation of the
hepatocytes.
More research is required to establish any true association
between cholecystectomy and hepatocellular carcinoma, but
assuming that a two-fold increased risk is true, the absolute risk
would increase from about 3 per 100000 persons and year to 6 per
100000 persons and year in Sweden. The individuals’ risk is,
therefore, still limited and the results should be used to influence
clinical decision-making in patients in need for cholecystectomy.
In conclusion, this population-based cohort study of 345251
people with nearly 5 million person-years at risk, with follow-up of
up to 43 years, indicates that cholecystectomy is associated with an
increased risk of hepatocellular carcinoma.
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